Anticancer peptides (ACPs) contain short peptides composed of 10–60 amino acids that can inhibit tumors cell
proliferation or migration, or suppress the formation of tumors blood vessels, and are less likely to cause drug resistance. The
aforementioned merits make ACPs the most promising anti-cancer candidate. ACPs may be degraded by proteases and result in
cytotoxicity in many cases.